The biopharma landscape has changed. In just a few years, nucleic acid therapeutics—once considered experimental—have become one of the most exciting frontiers in medicine. From mRNA vaccines to CRISPR-based therapies and antisense oligonucleotides, these molecules are reshaping how we think about treating disease.

At Xoligo Biologics, we launched with a clear vision: to build a boutique CDMO dedicated to nucleic acids, supported by deep expertise in oligonucleotides, mRNA, gene editing, and microbial systems. Where large, generalist CDMOs spread their focus across dozens of modalities, we chose to specialize. Our belief is simple: focus creates speed, quality, and innovation.

Why Xoligo Biologics?

• Precision in Oligos – Custom antisense, siRNA, aptamers, and CRISPR gRNAs, from discovery to preclinical scales.
• Next-Gen RNA – In vitro transcription platforms for mRNA, saRNA, and circRNA therapeutics.
• Microbial Foundations – Plasmid DNA, enzymes, and proteins produced through high-yield fermentation.
• End-to-End Continuity – Integrated services that move seamlessly from research to GMP.

We aren’t here to be another “full-service” CDMO. We’re here to be the partner of choice for innovators who see nucleic acids as the next chapter of medicine.

Innovations Driving 2025 and Beyond

The field of nucleic acid therapeutics is advancing at an extraordinary pace—and so are we. Each year brings a wave of breakthroughs that once felt like distant possibilities. At Xoligo Biologics, we’re not waiting for these technologies to mature before adapting; we are building capabilities now to ensure our clients can leverage tomorrow’s modalities today.

Here are a few of the innovations that we believe are defining 2025 and shaping the future of nucleic acid therapeutics:

Circular RNA (circRNA) Therapeutics

Circular RNAs are emerging as one of the most compelling frontiers in RNA medicine. Unlike conventional linear mRNA, circRNAs form closed-loop structures that lack free ends—making them inherently more resistant to exonuclease degradation. This confers superior stability, which translates into longer-lasting protein expression in vivo.

In 2025, circRNA platforms are moving from academic exploration into genuine clinical traction, particularly in oncology and rare genetic disorders. Their potential to deliver durable, controlled expression without repeated high dosing makes them especially attractive in fields where treatment burden is high. At Xoligo, we are exploring circRNA manufacturing workflows alongside traditional mRNA, ensuring clients can test, validate, and scale circRNA programs as demand accelerates.

Self-Amplifying RNA (saRNA)

Self-amplifying RNA represents a leap forward in therapeutic efficiency. Derived from alphavirus replicon systems, saRNA encodes both the therapeutic payload and the machinery to replicate itself inside the cell. The result: a single molecule of saRNA can generate multiple copies of the therapeutic RNA once delivered.

For developers, this translates to dramatically lower doses—sometimes 10- to 100-fold reductions compared to conventional mRNA—without sacrificing therapeutic effect. Lower doses mean lower manufacturing costs, reduced toxicity risks, and simplified supply chain logistics. In 2025, saRNA is gaining momentum not just in infectious disease vaccines, but in oncology immunotherapies and metabolic disorders.

Xoligo’s focus is to provide scalable IVT platforms that can accommodate saRNA constructs, helping clients explore this powerful modality with confidence.

Targeted Conjugates for Oligonucleotides

One of the greatest challenges in oligonucleotide therapeutics has always been delivery. Without a vehicle to reach the right tissue, even the most elegantly designed oligo fails. The field is now rapidly expanding beyond standard backbones into conjugated oligonucleotides—linking molecules to targeting moieties that guide them precisely where they need to go.

• GalNAc Conjugates – Already validated in multiple approved therapies, GalNAc delivers oligos efficiently to the liver.
• Novel Ligands – New chemistries are being explored for delivery to muscle, CNS, and immune tissues.
• Multifunctional Hybrids – Combining targeting, stability, and pharmacokinetic improvements into a single construct.

At Xoligo, we are investing in the ability to synthesize, purify, and characterize complex conjugated oligos, because delivery is not an afterthought—it is central to therapeutic success.

Microbial-Enabled Therapeutics

Behind every nucleic acid program lies a microbial foundation. Plasmid DNA, enzymes, and structural proteins are produced at scale through microbial fermentation, and advances in strain engineering are pushing the boundaries of what bacteria and yeast can deliver.

In 2025, microbial-enabled therapeutics are expanding into three key areas:

• High-Yield Plasmids – Optimized fermentation strategies are delivering cleaner, higher-yield plasmid DNA for RNA synthesis and gene editing.
• Enzyme Production – Polymerases, ligases, and novel enzymes are being tailored to improve transcription efficiency and reduce costs.
• Novel Biologics – Engineered microbes are now capable of producing capsid proteins, scaffolds, and even exosome-like particles for next-gen delivery systems.

At Xoligo Biologics, we integrate microbial fermentation directly into our nucleic acid platform, ensuring clients don’t need to stitch together fragmented supply chains. By doing so, we reduce risk and accelerate timelines—critical advantages in today’s competitive market.

These Are Not Buzzwords

Circular RNA, saRNA, conjugated oligos, and microbial-enabled therapeutics are not distant visions—they are the projects we’re supporting today. By aligning our capabilities with the most promising frontiers of 2025, we give clients a pathway to explore emerging science with a partner who is technically ready, strategically focused, and agile enough to adapt as the field evolves.

A Boutique Approach in a Big Market

The CDMO industry is dominated by multinational giants. But scale comes with trade-offs: bureaucracy, inflexibility, and a tendency to treat early-stage innovators as small projects in a crowded pipeline. We see things differently.

• Responsiveness instead of bureaucracy. You won’t wait weeks for answers—we move at the pace of science.
• Technical depth instead of generic project plans. We live and breathe nucleic acids, and our expertise reflects that focus.
• Partnership instead of transactional outsourcing. We act as an extension of your team, not just another vendor.

At Xoligo Biologics, our boutique approach is intentional. We combine the focus of a specialist lab with the infrastructure of a CDMO, giving clients both the intimacy of collaboration and the assurance of scalable delivery.

Looking Ahead

This blog will be our space to share:

• Insights into nucleic acid manufacturing and biotech trends, demystifying both the science and the business.
• Technical deep dives into oligo chemistry, RNA workflows, microbial fermentation, and analytical challenges.
• Spotlights on innovation, from circRNA breakthroughs to conjugate chemistries reshaping therapeutic delivery.

Most importantly, we want this space to reflect our philosophy: we’re here not only to offer services, but to contribute to the larger conversation shaping the future of medicine.

Welcome to Xoligo Biologics!

Boutique focus. Technical depth. A partner for the future of nucleic acid therapeutics.